All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

/images/Cortellis_Flagship_Logo_TM_RGB_Color.png
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • Diagnosing and tracking COVID-19
    • Drugs to Watch 2020
    • The next pandemic
    • Premium reports
      • BioWorld Financings Reports
      • Disease Forecast Reports

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, March 3, 2021
Home » Blogs » BioWorld Perspectives

BioWorld Perspectives
BioWorld Perspectives RSS FeedRSS

China: An Image Adjustment

June 17, 2011
By Tom Wall
No Comments
I’m an American baby boomer. For me – and I suspect many others of my generation – China’s image has not been the best. In my mental collage, fascination with Chinese culture and invention is offset by wariness of China’s political system and potential power. Some parts of the collage: as a boy, listening to stories told by a Korean War vet uncle and neighbors about hand-to-hand fighting with young Chinese soldiers wearing tennis shoes on their frozen feet at Chosin Reservoir; as a teen, accounts of Mao Zedong’s chaotic Cultural Revolution, its purges and Red Guards; in middle age,...
Read More

Biotech Series A Funding Up in 2011 . . . But There’s a Catch

June 14, 2011
By Trista Morrison
No Comments
Despite the fact that private biotechs raised just $1.76 billion in the first five months of 2011 – putting this year on pace to be not only worse than last year, but worse than the dreaded low of 2008 – Seed and Series A funding accounts for a bigger piece of the pie. You heard that right. According to data from BioWorld Insight and BioWorld Snapshots, Seed and Series A rounds accounted for a healthy 27.5 percent of private biotech funding so far in 2011, up from just 17.7 percent in 2010. Here’s the catch. The biggest start-up round this...
Read More

Equal Standards of Disclosure

June 10, 2011
By Mari Serebrov
No Comments
Disclosure and transparency. They’re recurring themes often sung by lawmakers and critics who would have us believe that even the gift of a drug-labeled pen will put doctors and medical students under the influence of biopharma. You’ve heard the refrain. Calls for disclosure on journal articles and citizen petitions. Reminders to disclose drug ties when testifying before Congress or an advisory committee. Requirements for doctors and researchers to disclose personal or family ties with industry when serving on an FDA advisory committee. What you haven’t heard are demands that biopharma critics disclose where they get their funding. And when’s the...
Read More

The Blame Game: BioPharma CEOs Shouldn't Be Scapegoats

June 9, 2011
By Ilene Schneider
No Comments
Biopharma CEOs sometimes pay for the sins of their companies. But is it fair to single out just one person when the failure of the company, or the unethical behavior of the company, is the result of many people's actions? Oddly, on the same day as I pondered this question, I read about Jim Tressel, the Ohio State University head football coach who resigned because of the violations of some of his players. Like cases involving biopharma CEOs, it leaves many questions unanswered, such as how much Tressel knew, whether he reported things...
Read More

@ASCO2011: Genomics Era of Cancer has Arrived – Like a Tsunami

June 4, 2011
By Anette Breindl
No Comments
CHICAGO ‑ As a scientist by training, I tend to look with unbridled optimism at technological advances. So it was striking to me to see how those that are expected to do something useful with such advances sometimes have a more nuanced take on them. Genomic technologies have led to a “tsunami of information,” outgoing ASCO president George Sledge told the audience in his plenary lecture. And it is a tsunami that the current clinical trials system, let alone the practicing oncologist, is in many ways unprepared for. Sledge is no Luddite. In fact, he spent much of his talk...
Read More

Truth in Congressional Labeling

June 1, 2011
By Mari Serebrov
No Comments
S. 990 was signed into law last week. At first glance, it looks like it extends the life of Small Business Administration programs that are near and dear to the bottom line of many small biotechs. But somewhere along its pat through the Senate, the bill was stripped of the language that would have extended the Small Business Innovation Research (SBIR) program through Sept. 30, 2012. In its place are a few short paragraphs renewing the Patriot Act. But the title of the bill remains “To provide for an additional temporary extension of programs under the Small Business Act and...
Read More

The Hottest Jobs in the Biotech’s Future

May 24, 2011
By Ilene Schneider
No Comments
What are the hot jobs in the life sciences during the next decade? According to Bernhard Palsson, of the University of California, San Diego, there is "unprecedented opportunity" in systems biology and bioinformatics, which seek not only biologists, but also engineers, chemists, mathematicians and computer programmers. "New systems biology centers are being established worldwide," added Lynn Hlatky, director of the center of cancer systems biology at St. Elizabeth's Medical Center at Tufts University in Boston. "To get a life science job in 10 or 20 years, you will simply be expected to have competency in these areas," said Jens Nielsen,...
Read More

Biotech’s Emerging Giant

May 24, 2011
By Lynn Yoffee
No Comments
While attending the China track at this year’s J.P. Morgan conference in January I sat next to a gentleman who was smiling as he scanned the jam-packed penthouse meeting room. Shooting him a questioning glance, he responded with “last year I attended there were five people here.” While I find it hard to believe a session on China was poorly attended, even a year ago, biotech and pharma executives were noticeably shoulder to shoulder, jockeying for position just a few months ago. Intensity over the Chinese market has certainly ramped up, to say the least. As company after Chinese company...
Read More

LJPC, GNTA Not Dead Yet

May 23, 2011
By Trista Morrison
No Comments
It looked Monday as if two of biotech’s long-suffering names might finally be biting the dust. Genta Inc. threw in the towel on beleaguered antisense drug Genasense (oblimersen sodium), after a final analysis of a Phase III melanoma trial – and a previous Phase III melanoma trial, and a Phase III chronic lymphocytic leukemia trial, and a Phase III multiple myeloma trial, and a melanoma approval bid, and a CLL approval bid, and a second CLL approval bid – failed. Meanwhile La Jolla Pharmaceutical Co., which already abandoned lupus drug Riquent (abetimus sodium) after years of mixed data and failed...
Read More

Race To Nowhere

May 19, 2011
By Anette Breindl
No Comments
Racial profiling – long in the realm of bad law enforcement – was criticized as bad medicine, too, in a recent paper by scientists from the Mount Sinai School of Medicine. The reason? As the authors put it, “cosmopolitan cities now include many individuals whose genetic heritage is drawn from multiple continental origins.” In other words, there’s no such thing as racial purity. In their paper, which was published in PLoS ONE and which you can find here (http://ow.ly/4YxK6) the team genotyped nearly 1,000 participants of Biobank, a program that collects DNA and plasma samples to aid in genomic and...
Read More
Previous 1 2 … 15 16 17 18 19 20 21 22 23 Next

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld

    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

  • Today's news in brief

    BioWorld
    BioWorld briefs for March 2.
  • Gloved hand places sample tubes in PCR system

    COVID-19 test makers are adapting for variants

    BioWorld MedTech
    As COVID-19 variants have emerged, so have questions about the effectiveness of tests for infection. While the risk of mutations significantly limiting their...
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech's briefs for March 2.
  • Celltrion-Regkirona-2-9

    Celltrion wins first conditional Korean approval for COVID-19 antibody Regkirona

    BioWorld
    HONG KONG – Celltrion Inc. has received conditional marketing authorization from the Ministry of Food and Drug Safety (MFDS) for its anti-COVID-19 monoclonal...
cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • About
    • Archives
    • Today's news
    • Search BioWorld Science
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
A Clarivate Analytic solution. Link to Clarivate website.
Follow Us

Copyright ©2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing